Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with certain types of peripheral T-cell lymphoma (PTCL) confirmed by a tissue sample, including subtypes such as PTCL not otherwise specified, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, nodal peripheral T-cell lymphoma with T-follicular helper phenotype, and follicular T-cell lymphoma.
• People aged between 18 and 80 years old.
• People who have not yet received any anti-cancer treatment for their lymphoma.
• People with a general health status rated as able to carry out normal daily activities or light work, or who are up and about more than half the day (confirm with trial site regarding the specific fitness scale used).
• People whose heart, liver, lung, and kidney function are within acceptable ranges, based on blood test results.
• People with normal blood cell counts, including adequate levels of white blood cells, red blood cells, and platelets.
• People who do not have any other serious illnesses that would conflict with the treatment plan.
• People who do not have any other cancer diagnoses.
• Women of childbearing age who have a negative pregnancy test at the time of enrolment.
• People with an estimated life expectancy of at least 3 months and who are able to follow the study requirements.
• People who are willing to participate voluntarily and have signed a written informed consent form.

Who may not be able to join:

• People whose PTCL subtype is one of the following: extranodal natural killer/T-cell lymphoma, T-prolymphocytic leukemia, T large granular lymphocytic leukemia, chronic lymphoproliferative disorder of NK cells, aggressive NK-cell leukemia, adult T-cell leukemia/lymphoma, hepatosplenic T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, cutaneous T-cell lymphoma, or breast implant-associated anaplastic large-cell lymphoma.
• People whose lymphoma has transformed from another type of lymphoma.
• People who have had, or currently have, any other cancer, or whose lymphoma developed as a result of chemotherapy or radiotherapy for another cancer.
• People who have already started lymphoma treatment (other than a specific pre-treatment allowed under this study).
• People whose lymphoma affects the brain or spinal cord, or the membranes surrounding them.
• People being considered for a stem cell transplant.
• People with a known allergy to any of the medications used in the trial.
• People whose blood cell counts fall below the required levels.
• People with known liver or kidney function that does not meet the required blood test thresholds.
• People with serious heart conditions, including severe heart failure, dilated cardiomyopathy, certain abnormal heart rhythm findings, or a heart attack within the past 6 months.
• People with serious uncontrolled infections currently requiring treatment, or with severely impaired organ function.
• People who have tested positive for HIV, hepatitis B surface antigen, or hepatitis C antibodies.
• People who are pregnant or breastfeeding.
• People who have participated in another clinical trial within the past 3 months.
• People whom the trial researchers determine should not participate, for any reason.

Important: Always verify eligibility with the trial site directly before applying.